|
BMS, Alder Reach Rheumatoid Arthritis Drug Agreement
Bristol-Myers Squibb (BMS) and Alder Biopharmaceuticals have reached a global agreement for the development and commercialization of ALD518, an innovative
monoclonal antibody that has completed Phase IIa testing as a treatment for rheumatoid arthritis.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives